Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | d946018dex991.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) June 23, 2015
CYNAPSUS THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
| Canada | 001-37426 | Not Applicable | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 828 Richmond Street West, Toronto, Ontario, Canada |
M6J 1C9 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 416-703-2449
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01. | Regulation FD Disclosure. |
On June 23, 2015, Cynapsus Therapeutics Inc. announced the closing of its previously announced underwritten public offering. The full text of the press release is being furnished as Exhibit 99.1 to this Form 8-K, and shall not be deemed filed under the Securities Exchange Act of 1934, as amended.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Number |
Description | |||
| 99.1 |
Press release dated June 23, 2015 | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 23, 2015 | CYNAPSUS THERAPEUTICS INC. | |||||
| By: | /s/ Anthony Giovinazzo | |||||
| Name: Anthony Giovinazzo | ||||||
| Title: President and Chief Executive Officer | ||||||
EXHIBITS FURNISHED WITH THIS REPORT
| Number | Description | |
| 99.1 | Press release dated June 23, 2015 | |